LinkedIn Profile

Access Mersana Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:mrsn 145888 Apr 21st, 2024 12:00AM Mersana Therapeutics 11K 172.00 Open Apr 20th, 2024 11:48PM Apr 20th, 2024 11:48PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 20th, 2024 12:00AM Mersana Therapeutics 11K 172.00 Open Apr 19th, 2024 11:45PM Apr 20th, 2024 05:20PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 19th, 2024 12:00AM Mersana Therapeutics 11K 172.00 Open Apr 18th, 2024 11:52PM Apr 18th, 2024 11:52PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 18th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 18th, 2024 12:01AM Apr 18th, 2024 06:40PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 17th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 16th, 2024 11:43PM Apr 17th, 2024 03:06PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 16th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 15th, 2024 11:39PM Apr 16th, 2024 11:22AM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 15th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 14th, 2024 11:34PM Apr 15th, 2024 05:03PM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 14th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 13th, 2024 11:23PM Apr 14th, 2024 11:22AM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 13th, 2024 12:00AM Mersana Therapeutics 11K 173.00 Open Apr 12th, 2024 11:15PM Apr 13th, 2024 11:49AM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics
nasdaq:mrsn 145888 Apr 12th, 2024 12:00AM Mersana Therapeutics 11K 175.00 Open Apr 11th, 2024 11:20PM Apr 12th, 2024 08:44AM At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Open cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology Open 840 Memorial Drive Cambridge MA US 02139 Mersana Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.